N

Nuvalent Inc
NASDAQ:NUVL

Watchlist Manager
Nuvalent Inc
NASDAQ:NUVL
Watchlist
Price: 99.32 USD 1.17% Market Closed
Market Cap: 7.2B USD
Section:
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

There is not enough data to reliably calculate the relative value of NUVL.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NUVL Relative Value
Base Case
Not Available
N
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-23.5
Median 5Y
-22.7
Industry
25
Forward
-18.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-30.1
Median 5Y
-28.7
Industry
20.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-30.1
Median 5Y
-28.7
Industry
22.5
More Details
8.5
P/B
P/B
Price to Book Value
8.5
vs History
5
vs Industry
18
Median 3Y
6.3
Median 5Y
5.7
Industry
3.2
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.1
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-17.9
Median 5Y
-17
Industry
6.1
Forward
-15.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-17.9
Median 5Y
-17
Industry
6.5
Forward
-14.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-24.1
Median 5Y
-23.6
Industry
7.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-24.1
Median 5Y
-23.6
Industry
5.7
More Details
421.4
EV/IC
EV/IC
Enterprise Value to IC
421.4
vs History
44
vs Industry
1
Median 3Y
467.5
Median 5Y
406.4
Industry
5.5
More Details

Multiples Across Competitors

NUVL Competitors Multiples
Nuvalent Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Nuvalent Inc
NASDAQ:NUVL
7.2B USD 0 -18.8 -15.7 -15.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 409 050.7 -163 541.1 -198 591.1 -196 324.9
US
Abbvie Inc
NYSE:ABBV
385.2B USD 6.6 103.5 16.9 24.5
US
Amgen Inc
NASDAQ:AMGN
160.6B USD 4.6 24.3 18.9 18.9
US
Gilead Sciences Inc
NASDAQ:GILD
148.8B USD 5.1 18.3 12.3 12.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 047.4 -522.4 -568.9 -553.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
109.1B USD 9.6 30 22.2 23.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
68.6B USD 4.8 15 14.1 16
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
59.7B USD 24.3 -187.2 -468.1 -321.3
AU
CSL Ltd
ASX:CSL
84.9B AUD 3.6 18.5 12.5 15.6
NL
argenx SE
XBRU:ARGX
43.2B EUR 13.9 32.6 55.9 57.5
P/S Multiple
Revenue Growth P/S to Growth
US
N
Nuvalent Inc
NASDAQ:NUVL
Average P/S: 3 441 117
Not Available 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 409 050.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
E
Epizyme Inc
F:EPE
2 047.4
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.8
5%
1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24.3
42%
0.6
AU
CSL Ltd
ASX:CSL
3.6
6%
0.6
NL
argenx SE
XBRU:ARGX
13.9
44%
0.3
P/E Multiple
Earnings Growth PEG
US
N
Nuvalent Inc
NASDAQ:NUVL
Average P/E: 34.6
Negative Multiple: -18.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 541.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
103.5
89%
1.2
US
Amgen Inc
NASDAQ:AMGN
24.3
44%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.3
191%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -522.4 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15
7%
2.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -187.2 N/A N/A
AU
CSL Ltd
ASX:CSL
18.5
14%
1.3
NL
argenx SE
XBRU:ARGX
32.6
34%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
N
Nuvalent Inc
NASDAQ:NUVL
Average EV/EBITDA: 21.8
Negative Multiple: -15.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 591.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.9
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.9
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -568.9 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
16%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.1
9%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -468.1 N/A N/A
AU
CSL Ltd
ASX:CSL
12.5
11%
1.1
NL
argenx SE
XBRU:ARGX
55.9
769%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
N
Nuvalent Inc
NASDAQ:NUVL
Average EV/EBIT: 24
Negative Multiple: -15.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 324.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.9
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
13%
0.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -553.7 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.2
17%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16
12%
1.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -321.3 N/A N/A
AU
CSL Ltd
ASX:CSL
15.6
14%
1.1
NL
argenx SE
XBRU:ARGX
57.5
N/A N/A

See Also

Summary
NUVL intrinsic value, competitors valuation, and company profile.
DCF Valuation
NUVL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NUVL stock valuation using valuation multiples.
Wall Street Estimates
NUVL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NUVL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 293,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.